Catalyst Wire Dossier Catalyst Wire Dossier

Welireg (Belzutifan)

belzutifan · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Welireg (Belzutifan), covering 2024-11-22 to 2025-07-10. Get the full timeline:

Most recent: Clinical Trial Update: A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) [Phase 1]

See pricing